医学
中医药
疾病
死因
纤维化
心肌缺血
重症监护医学
炎症
心力衰竭
心肌纤维化
缺血
心脏病学
内科学
替代医学
病理
作者
Lanlan Li,Yuping Ran,Jiao Wen,Yirui Lu,Shunmei Liu,Hong Li,Min Cheng
出处
期刊:Current Pharmaceutical Biotechnology
[Bentham Science]
日期:2024-02-12
卷期号:25
被引量:1
标识
DOI:10.2174/0113892010279151240116103917
摘要
Abstract: Cardiovascular Disease (CVD) is the leading cause of morbidity and death worldwide and has become a global public health problem. Traditional Chinese medicine (TCM) has been used in China to treat CVD and achieved promising results. Therefore, TCM has aroused significant interest among pharmacologists and medical practitioners. Previous research showed that TCM can regulate the occurrence and development of atherosclerosis (AS), ischemic heart disease, heart failure, myocardial injury, and myocardial fibrosis by inhibiting vascular endothelial injury, inflammation, oxidant stress, ischemia-reperfusion injury, and myocardial remodeling. It is well-known that TCM has the characteristics of multi-component, multi-pathway, and multitarget. Here, we systematically review the bioactive components, pharmacological effects, and clinical application of TCM in preventing and treating CVD.
科研通智能强力驱动
Strongly Powered by AbleSci AI